0

WAY-362450

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP629664819
CAS629664-81-9
Structure
MDL NumberMFCD13181507
Molecular Weight438.47
InChI KeyINASOKQDNHHMRE-UHFFFAOYSA-N
Description≥98% (HPLC)
SolubilityDMSO: 20 mg/mL, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size5MG, 25MG
Storage Conditionsroom temp
1

Chronic Activation of FXR-induced Liver Growth With Tissue-Specific Targeting Cyclin D1

Weibin Wu, Qing Wu, Xinmei Liu

Cell Cycle. 2019 Aug;18(15):1784-1797.

PMID: 31223053

1

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Brenton Flatt, Richard Martin, Tie-Lin Wang, Paige Mahaney, Brett Murphy, Xiao-Hui Gu, Paul Foster, Jiali Li, Parinaz Pircher, Mary Petrowski, Ira Schulman, Stefan Westin, Jay Wrobel, Grace Yan, Eric Bischoff, etc.

J Med Chem. 2009 Feb 26;52(4):904-7.

PMID: 19159286

1

Farnesoid X Receptor Agonist WAY-362450 Attenuates Liver Inflammation and Fibrosis in Murine Model of Non-Alcoholic Steatohepatitis

Songwen Zhang, Juan Wang, Qiangyuan Liu, Douglas C Harnish

J Hepatol. 2009 Aug;51(2):380-8.

PMID: 19501927

1

Role of Farnesoid X Receptor and Bile Acids in Alcoholic Liver Disease

Sharon Manley, Wenxing Ding

Acta Pharm Sin B. 2015 Mar;5(2):158-67.

PMID: 26579442

1

Src-mediated Crosstalk Between FXR and YAP Protects Against Renal Fibrosis

Dong-Hyun Kim, Hoon-In Choi, Jung Sun Park, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim

FASEB J. 2019 Oct;33(10):11109-11122.

PMID: 31298930

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode